# A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

> **NCT01941511** · PHASE1 · COMPLETED · sponsor: **GlycoMimetics Incorporated** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Rivipansel

## Key facts

- **NCT ID:** NCT01941511
- **Lead sponsor:** GlycoMimetics Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01941511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01941511, "A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01941511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*